Victor L Villemagne

List of Publications by Year
in descending order

203 papers	20,903 citations	15504 65 h-index	10734 138 g-index
263 all docs	263 docs citations	263 times ranked	15647 citing authors

#	Article	IF	Citations
1	Association between amyloid-beta deposition and cortical thickness in dementia with Lewy bodies. Australian and New Zealand Journal of Psychiatry, 2023, 57, 594-602.	2.3	2
2	Direct Comparison of the Tau PET Tracers ^{18}F-Flortaucipir and ^{18}F-MK-6240 in Human Subjects. Journal of Nuclear Medicine, 2022, 63, 108-116.	5.0	39
3	Assessing Reactive Astrogliosis with ^{18}F-SMBT-1 Across the Alzheimer Disease Spectrum. Journal of Nuclear Medicine, 2022, 63, 1560-1569.	5.0	29
4	First-in-Humans Evaluation of ^{18}F-SMBT-1, a Novel ^{18}F-Labeled Monoamine Oxidase-B PET Tracer for Imaging Reactive Astrogliosis. Journal of Nuclear Medicine, 2022, 63, 1551-1559.	5.0	30
5	Imaging of Reactive Astrogliosis by Positron Emission Tomography. Frontiers in Neuroscience, 2022, 16, 807435.	2.8	25
6	Reduced cortical cholinergic innervation measured using [18F]-FEOBV PET imaging correlates with cognitive decline in mild cognitive impairment. NeuroImage: Clinical, 2022, 34, 102992.	2.7	14
7	Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12307.	2.4	14
8	The Association Between Alzheimer's Disease-Related Markers and Physical Activity in Cognitively Normal Older Adults. Frontiers in Aging Neuroscience, 2022, 14, 771214.	3.4	8
9	Multicenter 18F-PI-2620 PET for In Vivo Braak Staging of Tau Pathology in Alzheimer's Disease. Biomolecules, 2022, 12, 458.	4.0	9
10	Mesial temporal tau in amyloid-β-negative cognitively normal older persons. Alzheimer's Research and Therapy, 2022, 14, 51.	6.2	12
11	Brain health correlates of mobility-related confidence. Experimental Gerontology, 2022, 163, 111776.	2.8	1
12	Insulin resistance, cognition and Alzheimer's disease biomarkers: Evidence that CSF Aβ42 moderates the association between insulin resistance and increased CSF tau levels. Neurobiology of Aging, 2022, 114, 38-48.	3.1	5
13	11C-PiB PET can underestimate brain amyloid-β burden when cotton wool plaques are numerous. Brain, 2022, 145, 2161-2176.	7.6	8
14	The heritability of amyloid burden in older adults: the Older Australian Twins Study. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 303-308.	1.9	7
15	^{18}F-PI-2620 Tau PET Improves the Imaging Diagnosis of Progressive Supranuclear Palsy. Journal of Nuclear Medicine, 2022, , jnumed.121.262854.	5.0	8
16	Cerebrospinal Fluid Neurofilament Light Predicts Risk of Dementia Onset in Cognitively Healthy Individuals and Rate of Cognitive Decline in Mild Cognitive Impairment: A Prospective Longitudinal Study. Biomedicines, 2022, 10, 1045.	3.2	1
17	Future Directions in Molecular Imaging of Neurodegenerative Disorders. Journal of Nuclear Medicine, 2022, 63, 68S-74S.	5.0	7
18	Visually Identified Tau 18F-MK6240 PET Patterns in Symptomatic Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, , 1-11.	2.6	7

#	Article	IF	Citations
19	Plasma metabolites associated with biomarker evidence of neurodegeneration in cognitively normal older adults. Journal of Neurochemistry, 2021, 159, 389-402.	3.9	20
20	Association of Î²-Amyloid Level, Clinical Progression, and Longitudinal Cognitive Change in Normal Older Individuals. Neurology, 2021, 96, e662-e670.	1.1	34
21	Mesial temporal tau is related to worse cognitive performance and greater neocortical tau load in amyloid-Î²â€"negative cognitively normal individuals. Neurobiology of Aging, 2021, 97, 41-48.	3.1	23
22	Association of naturally occurring antibodies to Î²-amyloid with cognitive decline and cerebral amyloidosis in Alzheimerâ€™s disease. Science Advances, 2021, 7, .	10.3	26
23	Non-negative matrix factorisation improves Centiloid robustness in longitudinal studies. NeuroImage, 2021, 226, 117593.	4.2	15
24	SPON1 Is Associated with Amyloid-Î² and APOE Îµ4-Related Cognitive Decline in Cognitively Normal Adults. Journal of Alzheimer's Disease Reports, 2021, 5, 111-120.	2.2	5
25	Molecular Imaging Approaches in Dementia. Radiology, 2021, 298, 517-530.	7.3	27
26	Early detection of amyloid load using 18F-florbetaben PET. Alzheimer's Research and Therapy, 2021, 13, 67.	6.2	26
27	Cortical [^{18}F]PIâ€‘2620 Binding Differentiates Corticobasal Syndrome Subtypes. Movement Disorders, 2021, 36, 2104-2115.	3.9	46
28	Advances in Brain Amyloid Imaging. Seminars in Nuclear Medicine, 2021, 51, 241-252.	4.6	30
29	Androgen receptor CAG repeat length as a moderator of the relationship between free testosterone levels and cognition. Hormones and Behavior, 2021, 131, 104966.	2.1	2
30	Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimerâ€™s Disease. Journal of Alzheimer's Disease Reports, 2021, 5, 443-468.	2.2	59
31	Chronic stress and Alzheimer's disease: theâ€‰interplay between the hypothalamicâ€"pituitaryâ€"adrenal axis, genetics and microglia. Biological Reviews, 2021, 96, 2209-2228.	10.4	37
32	Postmortem Neocortical 3H-PiB Binding and Levels of Unmodified and Pyroglutamate AÎ² in Down Syndrome and Sporadic Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2021, 13, 728739.	3.4	2
33	The Amyloid-Î² Pathway in Alzheimerâ€™s Disease. Molecular Psychiatry, 2021, 26, 5481-5503.	7.9	478
34	Comparing Pathological Risk Factors for Dementia between Cognitively Normal Japanese and Americans. Brain Sciences, 2021, 11, 1180.	2.3	0
35	Relationship between amyloid and tau levels and its impact on tau spreading. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2225-2232.	6.4	30
36	What Is T+? A Gordian Knot of Tracers, Thresholds, and Topographies. Journal of Nuclear Medicine, 2021, 62, 614-619.	5.0	21

#	Article	IF	Citations
37	AÎ² Imaging in Aging, Alzheimerâ€™s Disease, and Other Neurodegenerative Conditions. , 2021, , 283-343.		0
38	Higher Coffee Consumption Is Associated With Slower Cognitive Decline and Less Cerebral AÎ²-Amyloid Accumulation Over 126 Months: Data From the Australian Imaging, Biomarkers, and Lifestyle Study. Frontiers in Aging Neuroscience, 2021, 13, 744872.	3.4	17
39	Relationship between amyloid and tau levels and its impact on tau spreading. Alzheimer's and Dementia, 2021, 17, .	0.8	1
40	Towards a universal cortical tau sampling mask. Alzheimer's and Dementia, 2021, 17, .	0.8	3
41	Examining the structural correlates of amyloidâ€beta in people with DLB. Alzheimer's and Dementia, 2021, 17, .	0.8	0
42	Effect of a 24-month physical activity program on brain changes in older adults at risk of Alzheimer's disease: the AIBL active trial. Neurobiology of Aging, 2020, 89, 132-141.	3.1	28
43	Identification of Pre-Clinical Alzheimerâ€™s Disease in a Population of Elderly Cognitively Normal Participants. Journal of Alzheimer's Disease, 2020, 73, 683-693.	2.6	0
44	Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. Lancet Neurology, The, 2020, 19, 951-962.	10.2	254
45	Comparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease. NeuroImage: Clinical, 2020, 28, 102491.	2.7	17
46	In vivo microstructural heterogeneity of white matter lesions in healthy elderly and Alzheimer's disease participants using tissue compositional analysis of diffusion MRI data. NeuroImage: Clinical, 2020, 28, 102479.	2.7	19
47	Plasma Amyloid-Î² Biomarker Associated with Cognitive Decline in Preclinical Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2020, 77, 1057-1065.	2.6	27
48	Assessment of ^{18}F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy. JAMA Neurology, 2020, 77, 1408.	9.0	145
49	A headâ€toâ€head comparison of cerebral blood flow SPECT and 18 Fâ€FDG PET in the diagnosis of Alzheimer's Disease. Internal Medicine Journal, 2020, 51, 1243-1250.	0.8	8
50	Relationships Between Plasma Lipids Species, Gender, Risk Factors, and Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2020, 76, 303-315.	2.6	23
51	Plasma transferrin and hemopexin are associated with altered AÎ² uptake and cognitive decline in Alzheimerâ€™s disease pathology. Alzheimer's Research and Therapy, 2020, 12, 72.	6.2	19
52	Impact of APOE-Îµ4 carriage on the onset and rates of neocortical AÎ²-amyloid deposition. Neurobiology of Aging, 2020, 95, 46-55.	3.1	32
53	Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2020, 12, 22.	6.2	74
54	Total AÎ²$_{42}$/AÎ²$_{40}$ ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis. Neurology, 2020, 94, e1580-e1591.	1.1	102

#	Article	IF	Citations
55	Early-phase [18F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2911-2922.	6.4	36
56	Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging. Alzheimer's Research and Therapy, 2020, 12, 36.	6.2	39
57	Comorbidity of Cerebrovascular andÂAlzheimerâ€™s Disease in Aging. Journal of Alzheimer's Disease, 2020, 78, 321-334.	2.6	4
58	[¹⁸F]THK5351 PET Imaging in Patients with Mild Cognitive Impairment. Journal of Clinical		

#	Article	IF	Citations
73	Cognitive gene risk profile for the prediction of cognitive decline in presymptomatic Alzheimer's disease. Personalized Medicine in Psychiatry, 2018, 7-8, 14-20.	0.1	13
74	Reply: Cortical tau pathology: a major player in fibre-specific white matter reductions in Alzheimer's disease?. Brain, 2018, 141, e45-e45.	7.6	4
75	Imaging tau and amyloid-Î² proteinopathies in Alzheimer disease and other conditions. Nature Reviews Neurology, 2018, 14, 225-236.	10.1	321
76	High performance plasma amyloid-Î² biomarkers for Alzheimer's disease. Nature, 2018, 554, 249-254.	27.8	1,180
77	KIBRA is associated with accelerated cognitive decline and hippocampal atrophy in APOE Îµ4-positive cognitively normal adults with high AÎ²-amyloid burden. Scientific Reports, 2018, 8, 2034.	3.3	31
78	Association of Î²-Amyloid and Apolipoprotein E Îµ4 With Memory Decline in Preclinical Alzheimer Disease. JAMA Neurology, 2018, 75, 488.	9.0	70
79	Amyloid burden and incident depressive symptoms in preclinical Alzheimer's disease. Journal of Affective Disorders, 2018, 229, 269-274.	4.1	27
80	Fibre-specific white matter reductions in Alzheimer's disease and mild cognitive impairment. Brain, 2018, 141, 888-902.	7.6	226
81	Selective Tau Imaging: <i>Der Stand der Dinge</i>. Journal of Nuclear Medicine, 2018, 59, 175-176.	5.0	17
82	Association of Cerebral Amyloid-Î² Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	11.0	133
83	ICâ€Pâ€223: TO TAU OR TO MAOâ€B? MOST OF THE [Fâ€18]â€THK5351 SIGNAL IS BLOCKED BY SELEGILINE. Alzheimer's and Dementia, 2018, 14, P181.	0.8	0
84	O1â€04â€01: PRECLINICAL ALZHEIMER'S DISEASE IS ASSOCIATED WITH LEARNING IMPAIRMENTS OVER SIX DAYS: RESULTS FROM THE ONLINE REPEATED COGNITIVE ASSESSMENT (ORCA) STUDY. Alzheimer's and Dementia, 2018, 14, P223.	0.8	0
85	Centiloid scaling for quantification of brain amyloid with [18F]flutemetamol using multiple processing methods. EJNMMI Research, 2018, 8, 107.	2.5	55
86	Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study. Journal of Alzheimer's Disease, 2018, 66, 1193-1211.	2.6	27
87	A Polygenic Risk Score Derived From Episodic Memory Weighted Genetic Variants Is Associated With Cognitive Decline in Preclinical Alzheimer's Disease. Frontiers in Aging Neuroscience, 2018, 10, 423.	3.4	16
88	O3â€04â€05: EVALUATION OF [Fâ€18]â€PIâ€2620, A SECONDâ€GENERATION SELECTIVE TAU TRACER, FOR THE ASSESSMENT OF ALZHEIMER'S AND NONâ€ALZHEIMER'S TAUOPATHIES. Alzheimer's and Dementia, 2018, 14, P1021.	0.8	2
89	Relationship Between Amyloid-Î² Positivity and Progression to Mild Cognitive Impairment or Dementia over 8 Years in Cognitively Normal Older Adults. Journal of Alzheimer's Disease, 2018, 65, 1313-1325.	2.6	19
90	Sex, amyloid, and <i>APOE</i> Îµ4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three wellâ€characterized cohorts. Alzheimer's and Dementia, 2018, 14, 1193-1203.	0.8	169

#	Article	IF	Citations
91	Targeting metals rescues the phenotype in an animal model of tauopathy. Metallomics, 2018, 10, 1339-1347.	2.4	20
92	Implementing the centiloid transformation for 11C-PiB and β-amyloid 18F-PET tracers using CapAIBL. NeuroImage, 2018, 183, 387-393.	4.2	94
93	Estimates of age-related memory decline are inflated by unrecognized Alzheimer's disease. Neurobiology of Aging, 2018, 70, 170-179.	3.1	14
94	Amyloid burden and incident depressive symptoms in cognitively normal older adults. International Journal of Geriatric Psychiatry, 2017, 32, 455-463.	2.7	49
95	Optimal Reference Region to Measure Longitudinal Amyloid-β Change with ^{18}F-Florbetaben PET. Journal of Nuclear Medicine, 2017, 58, 1300-1306.	5.0	49
96	Effect of APOE Genotype on Amyloid Deposition, Brain Volume, and Memory in Cognitively Normal Older Individuals. Journal of Alzheimer's Disease, 2017, 58, 1293-1302.	2.6	35
97	A 'Disease Severity Index' to identify individuals with Subjective Memory Decline who will progress to mild cognitive impairment or dementia. Scientific Reports, 2017, 7, 44368.	3.3	23
98	Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 179-187.	2.4	129
99	Assessment of amyloid β in pathologically confirmed frontotemporal dementia syndromes. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 9, 10-20.	2.4	38
100	Tau positron emission tomography using [18F]THK5351 and cerebral glucose hypometabolism in Alzheimer's disease. Neurobiology of Aging, 2017, 59, 210-219.	3.1	50
101	Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms. Journal of Alzheimer's Disease, 2017, 61, 169-183.	2.6	21
102	18F-Florbetaben PET beta-amyloid binding expressed in Centiloids. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2053-2059.	6.4	87
103	Amyloid β–associated cognitive decline in the absence of clinical disease progression and systemic illness. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 156-164.	2.4	19
104	Aβ-amyloid and Tau Imaging in Dementia. Seminars in Nuclear Medicine, 2017, 47, 75-88.	4.6	96
105	Plasma Cortisol, Brain Amyloid-β, and Cognitive Decline in Preclinical Alzheimer's Disease: A 6-Year Prospective Cohort Study. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2017, 2, 45-52.	1.5	32
106	[P4–134]: INSULIN RESISTANCE IS ASSOCIATED WITH REDUCTIONS IN SPECIFIC COGNITIVE DOMAINS AND INCREASES IN CSF TAU IN COGNITIVELY NORMAL ADULTS. Alzheimer's and Dementia, 2017, 13, P1308.	0.8	0
107	[P4–269]: COMPARISON OF ^{18}F–FLORBETABEN QUANTIFICATION RESULTS USING MR–BASED AND MR–LESS CAPAIBL: VALIDATION AGAINST HISTOPATHOLOGY. Alzheimer's and Dementia, 2017, 13, P1387.	0.8	0
108	[IC–P–165]: FIXEL–BASED ANALYSIS OF FIBRE TRACT DEGENERATION IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P124.	0.8	1

#	Article	IF	Citations
109	[P4â€"499]: REFINING THE NATURAL HISTORY OF GLOBAL AND REGIONAL Aβâ€AMYLOID DEPOSITION IN SPORADIC ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P1530.	0.8	0
110	Cerebral quantitative susceptibility mapping predicts amyloid-β-related cognitive decline. Brain, 2017, 140, 2112-2119.	7.6	213
111	Tau imaging with PET: an overview of challenges, current progress, and future applications. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2017, 61, 405-413.	0.7	11
112	PL-05-01: The Challenges ahead for Pet Imaging of Progressive Proteinopathies. , 2016, 12, P374-P374.		1
113	Aβ-related memory decline in <i>APOE</i> ε4 noncarriers. Neurology, 2016, 86, 1635-1642.	1.1	37
114	Acceleration of hippocampal atrophy rates in asymptomatic amyloidosis. Neurobiology of Aging, 2016, 39, 99-107.	3.1	34
115	β-Amyloid, APOE and BDNF Genotype, and Depressive and Anxiety Symptoms in Cognitively Normal Older Women and Men. American Journal of Geriatric Psychiatry, 2016, 24, 1191-1195.	1.2	25
116	Performance on the Cogstate Brief Battery Is Related to Amyloid Levels and Hippocampal Volume in Very Mild Dementia. Journal of Molecular Neuroscience, 2016, 60, 362-370.	2.3	14
117	Untangling tau imaging. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 4, 39-42.	2.4	4
118	A Conceptualization of the Utility of Subjective Cognitive Decline in Clinical Trials of Preclinical Alzheimer's Disease. Journal of Molecular Neuroscience, 2016, 60, 354-361.	2.3	37
119	Predicting Alzheimer disease from a blood-based biomarker profile. Neurology, 2016, 87, 1093-1101.	1.1	26
120	Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study. Lancet Neurology, The, 2016, 15, 1044-1053.	10.2	175
121	Innate phagocytosis by peripheral blood monocytes is altered in Alzheimer's disease. Acta Neuropathologica, 2016, 132, 377-389.	7.7	40
122	CapAIBL: Automated Reporting of Cortical PET Quantification Without Need of MRI on Brain Surface Using a Patch-Based Method. Lecture Notes in Computer Science, 2016, , 109-116.	1.3	6
123	Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: Introducing the Zâ€scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 2, 19-26.	2.4	72
124	Standardized Expression of ^{18}F-NAV4694 and ^{11}C-PiB β-Amyloid PET Results with the Centiloid Scale. Journal of Nuclear Medicine, 2016, 57, 1233-1237.	5.0	80
125	Amyloid imaging: Past, present and future perspectives. Ageing Research Reviews, 2016, 30, 95-106.	10.9	43
126	Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 796-804.	0.8	135

#	Article	IF	Citations
127	Neuroimaging biomarkers in Alzheimer's disease and other dementias. Ageing Research Reviews, 2016, 30, 4-16.	10.9	32
128	Divergent Network Patterns of Amyloid-Î² Deposition in Logopenic and Amnestic Alzheimer's Disease Presentations. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2016, 1, 24-31.	1.5	3
129	Positron Emission Tomographic Imaging in Stroke. Stroke, 2016, 47, 113-119.	2.0	33
130	Tau imaging in the study of ageing, Alzheimer's disease, and other neurodegenerative conditions. Current Opinion in Neurobiology, 2016, 36, 43-51.	4.2	66
131	Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease. Brain, 2016, 139, 2528-2539.	7.6	58
132	Non-Verbal Episodic Memory Deficits in Primary Progressive Aphasias are Highly Predictive of Underlying Amyloid Pathology. Journal of Alzheimer's Disease, 2016, 51, 367-376.	2.6	37
133	Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated inÂPET Amyloid-Î² Characterized Subjects from the Australian Imaging, Biomarkers andÂLifestyle (AIBL) study. Journal of Alzheimer's Disease, 2015, 48, 175-187.	2.6	47
134	Peripheral Î±-Defensins 1 and 2 are Elevated in Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 44, 1131-1143.	2.6	15
135	Amyloid-Related Memory Decline in Preclinical Alzheimer's Disease Is Dependent on APOE Îµ4 and Is Detectable over 18-Months. PLoS ONE, 2015, 10, e0139082.	2.5	22
136	IC-P-016: Amyloid imaging in therapeutic trials: The quest for the optimal reference region. , 2015, 11, P21-P22.		7
137	Computer-aided detection of cerebral microbleeds in susceptibility-weighted imaging. Computerized Medical Imaging and Graphics, 2015, 46, 269-276.	5.8	35
138	APOE Îµ4 moderates amyloid-related memory decline in preclinical Alzheimer's disease. Neurobiology of Aging, 2015, 36, 1239-1244.	3.1	75
139	Basal forebrain atrophy correlates with amyloid Î² burden in Alzheimer's disease. NeuroImage: Clinical, 2015, 7, 105-113.	2.7	89
140	Comparison of MR-less PiB SUVR quantification methods. Neurobiology of Aging, 2015, 36, S159-S166.	3.1	96
141	Relationships Between Performance on the Cogstate Brief Battery, Neurodegeneration, and AÂ Accumulation in Cognitively Normal Older Adults and Adults with MCI. Archives of Clinical Neuropsychology, 2015, 30, 49-58.	0.5	40
142	Trajectories of memory decline in preclinical Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing. Neurobiology of Aging, 2015, 36, 1231-1238.	3.1	71
143	Amyloid-Î², Anxiety, and Cognitive Decline in Preclinical Alzheimer Disease. JAMA Psychiatry, 2015, 72, 284.	11.0	160
144	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	7.4	1,166

#	Article	IF	Citations
145	Prevalence of Amyloid PET Positivity in Dementia Syndromes. JAMA - Journal of the American Medical Association, 2015, 313, 1939.	7.4	501
146	Tau imaging: early progress and future directions. Lancet Neurology, The, 2015, 14, 114-124.	10.2	432
147	Aβ imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 431-436.	1.9	78
148	MR-Less Surface-Based Amyloid Assessment Based on 11C PiB PET. PLoS ONE, 2014, 9, e84777.	2.5	43
149	Effect of BDNF Val66Met on Memory Decline and Hippocampal Atrophy in Prodromal Alzheimer's Disease: A Preliminary Study. PLoS ONE, 2014, 9, e86498.	2.5	75
150	Cerebral Microbleeds: A Review of Clinical, Genetic, and Neuroimaging Associations. Frontiers in Neurology, 2014, 4, 205.	2.4	176
151	Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET. Brain, 2014, 137, 1762-1771.	7.6	234
152	Efficient machine learning framework for computer-aided detection of cerebral microbleeds using the Radon transform. , 2014, , .		21
153	Influence of <i>BDNF</i> Val66Met on the relationship between physical activity and brain volume. Neurology, 2014, 83, 1345-1352.	1.1	58
154	Imago Mundi, Imago AD, Imago ADNI. Alzheimer's Research and Therapy, 2014, 6, 62.	6.2	5
155	In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 816-826.	6.4	156
156	Assessing THK523 selectivity for tau deposits in Alzheimer's disease and non–Alzheimer's disease tauopathies. Alzheimer's Research and Therapy, 2014, 6, 11.	6.2	68
157	Aβ and cognitive change: Examining the preclinical and prodromal stages of Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 743.	0.8	66
158	In vivo tau imaging: Obstacles and progress. , 2014, 10, S254-S264.		84
159	Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 53-61.	0.8	114
160	Amyloid-β Related Memory Decline is not Associated with Subjective or Informant Rated Cognitive Impairment in Healthy Adults. Journal of Alzheimer's Disease, 2014, 43, 677-686.	2.6	63
161	P1-257: DOES ENHANCED RECONSTRUCTION METHODOLOGY CHANGE THE QUANTIFICATION OF AMYLOID PET WITH FLUMETAMOL?. , 2014, 10, P401-P402.		1
162	18F-florbetaben Aβ imaging in mild cognitive impairment. Alzheimer's Research and Therapy, 2013, 5, 4.	6.2	49

#	Article	IF	Citations
163	Regional variability of imaging biomarkers in autosomal dominant Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E4502-9.	7.1	309
164	Automatic detection of small spherical lesions using multiscale approach in 3D medical images. , 2013, , .		5
165	Predicting Alzheimer disease with Î²â€‘amyloid imaging: Results from the Australian imaging, biomarkers, and lifestyle study of ageing. Annals of Neurology, 2013, 74, 905-913.	5.3	194
166	AÎ² amyloid, cognition, and <i>APOE</i> genotype in healthy older adults. Alzheimer's and Dementia, 2013, 9, 538-545.	0.8	51
167	Amyloid Î² deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurology, The, 2013, 12, 357-367.	10.2	1,738
168	BDNF Val66Met, AÎ² amyloid, and cognitive decline in preclinical Alzheimer's disease. Neurobiology of Aging, 2013, 34, 2457-2464.	3.1	109
169	Cross-sectional and Longitudinal Analysis of the Relationship Between AÎ² Deposition, Cortical Thickness, and Memory in Cognitively Unimpaired Individuals and in Alzheimer Disease. JAMA Neurology, 2013, 70, 903.	9.0	170
170	Novel ¹⁸F-Labeled Arylquinoline Derivatives for Noninvasive Imaging of Tau Pathology in Alzheimer Disease. Journal of Nuclear Medicine, 2013, 54, 1420-1427.	5.0	259
171	Head-to-Head Comparison of ¹¹C-PiB and ¹⁸F-AZD4694 (NAV4694) for Î²-Amyloid Imaging in Aging and Dementia. Journal of Nuclear Medicine, 2013, 54, 880-886.	5.0	145
172	Differential Diagnosis in AlzheimerÂ's Disease and Dementia with Lewy Bodies via VMAT2 and Amyloid Imaging. Neurodegenerative Diseases, 2012, 10, 161-165.	1.4	37
173	Regional dynamics of amyloid-Î² deposition in healthy elderly, mild cognitive impairment and Alzheimerâ€™s disease: a voxelwise PiBâ€"PET longitudinal study. Brain, 2012, 135, 2126-2139.	7.6	222
174	ICâ€O3â€01: <i>In vivo</i> tau imaging in Alzheimer's disease and other dementias. Alzheimer's and Dementia, 2012, 8, P9.	0.8	3
175	The challenges of tau imaging. Future Neurology, 2012, 7, 409-421.	0.5	82
176	In vitro characterization of [18F]-florbetaben, an AÎ² imaging radiotracer. Nuclear Medicine and Biology, 2012, 39, 1042-1048.	0.6	54
177	Comparison of 11C-PiB and 18F-florbetaben for AÎ² imaging in ageing and Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 983-989.	6.4	161
178	AÎ² Imaging: feasible, pertinent, and vital to progress in Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 209-219.	6.4	55
179	Independent contribution of temporal Î²-amyloid deposition to memory decline in the pre-dementia phase of Alzheimerâ€™s disease. Brain, 2011, 134, 798-807.	7.6	132
180	IC-03-01: Dynamic of beta-amyloid deposition in healthy elderly, mild cognitive impairment and alzheimer's disease: a PiB-PET longitudinal study. , 2011, 7, S6-S6.		0

#	Article	IF	Citations
181	In Vivo Assessment of Vesicular Monoamine Transporter Type 2 in Dementia With Lewy Bodies and Alzheimer Disease. Archives of Neurology, 2011, 68, 905.	4.5	38
182	Cognition and beta-amyloid in preclinical Alzheimer's disease: Data from the AIBL study. Neuropsychologia, 2011, 49, 2384-2390.	1.6	139
183	Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Annals of Neurology, 2011, 69, 181-192.	5.3	730
184	Subtypes of progressive aphasia: application of the international consensus criteria and validation using β-amyloid imaging. Brain, 2011, 134, 3030-3043.	7.6	294
185	Local intensity model: An outlier detection framework with applications to white matter hyperintensity segmentation. , 2011, , .		5
186	Brain Amyloid Imaging. Journal of Nuclear Medicine, 2011, 52, 1733-1740.	5.0	226
187	Amyloid Imaging with 18F-Florbetaben in Alzheimer Disease and Other Dementias. Journal of Nuclear Medicine, 2011, 52, 1210-1217.	5.0	311
188	18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. Brain, 2011, 134, 1089-1100.	7.6	299
189	Relationship between atrophy and β‑amyloid deposition in Alzheimer disease. Annals of Neurology, 2010, 67, 317-324.	5.3	322
190	Larger temporal volume in elderly with high versus low beta-amyloid deposition. Brain, 2010, 133, 3349-3358.	7.6	130
191	Amyloid PET Ligands for Dementia. PET Clinics, 2010, 5, 33-53.	3.0	23
192	Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiology of Aging, 2010, 31, 1275-1283.	3.1	885
193	High Striatal Amyloid β-Peptide Deposition Across Different Autosomal Alzheimer Disease Mutation Types. Archives of Neurology, 2009, 66, 1537-44.	4.5	156
194	The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. International Psychogeriatrics, 2009, 21, 672-687.	1.0	661
195	The ART of Loss: Aβ Imaging in the Evaluation of Alzheimer's Disease and other Dementias. Molecular Neurobiology, 2008, 38, 1-15.	4.0	94
196	Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurology, The, 2008, 7, 129-135.	10.2	631
197	Appearance modeling of 11C PiB PET images: Characterizing amyloid deposition in Alzheimer's disease, mild cognitive impairment and healthy aging. NeuroImage, 2008, 43, 430-439.	4.2	81
198	MR-Less High Dimensional Spatial Normalization of 11C PiB PET Images on a Population of Elderly, Mild Cognitive Impaired and Alzheimer Disease Patients. Lecture Notes in Computer Science, 2008, 11, 442-449.	1.3	15

#	Article	IF	Citations
199	<i>In Vitro</i>Characterization of Pittsburgh Compound-B Binding to Lewy Bodies. Journal of Neuroscience, 2007, 27, 10365-10371.	3.6	154
200	Â-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain, 2007, 130, 2837-2844.	7.6	739
201	Evaluating Atypical Dementia Syndromes Using Positron Emission Tomography With Carbon 11â€"Labeled Pittsburgh Compound B. Archives of Neurology, 2007, 64, 1140.	4.5	72
202	Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics. Journal of Neurochemistry, 2006, 97, 1700-1725.	3.9	206
203	Imaginem oblivionis: the prospects of neuroimaging for early detection of Alzheimer's disease. Journal of Clinical Neuroscience, 2005, 12, 221-230.	1.5	51